Almetuzamab: Promise in Multiple Sclerosis; UK Research
October 25th, 2008
Published this week in the New England Journal of Medicine, promising trial data for the new monoclonal antibody Almetuzamab.The conclusions of the study were as follows: “ In patients with early, relapsing–remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura. The study [...]